Clinical trials: Open-label
Randomized, Open-label
A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)
A randomized, multicenter, open-label, active-controlled Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of multiple intravaginal doses of GenSci142 in patients with bacterial…
- Conditions
- Randomized, Open-label, Safety, Tolerability
- Trial name
- NCT07663838
- Testing
- GenSci142 capsule, clindamycin phosphate vaginal cream
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Advanced Urothelial Carcinoma, Oral Drug Administration
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma.
- Conditions
- Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
- Trial name
- NCT05929235
- Testing
- FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 120 people
- Sponsor
- Flare Therapeutics Inc.
Pharmakokinetic, Open Label
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
TNX-102 SL has recently been approved by the United States (US) Food and Drug Administration (FDA) under the brand name TONMYA for the treatment of fibromyalgia.
- Conditions
- Pharmakokinetic, Open Label, Phase 1
- Trial name
- NCT07413367
- Testing
- TNX-102 SL Tablet
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tonix Pharmaceuticals, Inc.
Pharmacokinetics, Open Label
A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers
The purpose of this study is to investigate the effect of administration of CAZ-AVI and CXL on the intestinal flora of male and female healthy volunteers after multiple administrations over 7 days.
- Conditions
- Pharmacokinetics, Open Label, CAZ-AVI, CXL
- Trial name
- NCT01789528
- Testing
- CAZ-AVI, CXL
- Where
- Sweden
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer